UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of the Securities Exchange Act of
1934
Date
of Report (Date of earliest event reported):
|
July
4, 2008
|
BIO-BRIDGE
SCIENCE, INC.
|
(Exact
name of registrant as specified in its
charter)
|
Delaware
|
|
|
|
20-1802936
|
(State
or other jurisdiction of incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer Identification No.)
|
1211
West 22nd Street, Suite 615, Oak Brook, Illinois
|
|
60523
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code:
|
630-928-0869
|
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
o
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
This
Form 8-K and other reports filed by the Registrant from time to time with
the
Securities and Exchange Commission (collectively the “Filings”) contain forward
looking statements and information that are based upon beliefs of, and
information currently available to, the Registrant’s management as well as
estimates and assumptions made by the Registrant’s management. When used in the
Filings the words “anticipate”, “believe”, “estimate”, “expect”, “future”,
“intend”, “plan” or the negative of these terms and similar expressions as they
relate to the Registrant or the Registrant’s management identify forward looking
statements. Such statements reflect the current view of the Registrant with
respect to future events and are subject to risks, uncertainties, assumptions
and other factors relating to the Registrant’s industry, operations and results
of operations and any businesses that may be acquired by the Registrant.
Should
one or more of these risks or uncertainties materialize, or should the
underlying assumptions prove incorrect, actual results may differ significantly
from those anticipated, believed, estimated, expected, intended or
planned.
Item
8.01 Other Events
As
used
in this report, "we", "us", "our" or "BGES" refer to Bio-Bridge Science,
Inc., a
Delaware corporation and its subsidiaries.
On
July
4, Bio-Bridge Science Inc. received a certificate of approval from Department
of
Commerce of Inner Mongolia Autonomous Region of the PRC for approving the
acquisition of Xinheng Baide Biotechnology Co. Ltd. The Company has one month
from the approval date to close the transaction and obtain a new business
license. The transaction is expected to close before the end of July.
Item
9.01 Financial Statements and Exhibits
(c)
Exhibits.
Exhibit Number
|
|
Description
|
99.1
|
|
Press
release dated July 8, 2008
|
|
|
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
|
BIO-BRIDGE
SCIENCE, INC.
|
|
|
|
|
|
|
Date:
July
8, 2008
|
By:
|
|
/s/
Liang Qiao, MD.
|
|
|
Name:
|
|
Liang
Qiao, MD.
|
|
|
Title:
|
|
Chief
Executive Officer
|
|
|
|
|
|